Tag Archives: ERBITUX

Merck KGaA Partners with Inspirna to Advance Novel Therapy for RAS-mutated Colorectal Cancer

(IN BRIEF) Merck KGaA, Darmstadt, Germany, has entered into a licensing agreement with Inspirna, Inc. for ompenaclid (RGX-202), a first-in-class oral inhibitor of the creatine transport channel SLC6A8, and SLC6A8-targeting follow-on compounds, currently under Phase II evaluation for the second-line … Read the full press release

Merck to Showcase Oncology Portfolio Advancements at ESMO 2023, Highlighting Key Cancer Treatment Breakthroughs

(IN BRIEF) Merck, a leading science and technology company, is set to present 28 abstracts at the 2023 European Society of Medical Oncology (ESMO) Annual Meeting in Madrid. These abstracts will showcase the latest research on Merck’s oncology portfolio, addressing … Read the full press release